EA201700456A1 - Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf - Google Patents

Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf

Info

Publication number
EA201700456A1
EA201700456A1 EA201700456A EA201700456A EA201700456A1 EA 201700456 A1 EA201700456 A1 EA 201700456A1 EA 201700456 A EA201700456 A EA 201700456A EA 201700456 A EA201700456 A EA 201700456A EA 201700456 A1 EA201700456 A1 EA 201700456A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
nucleotide sequence
volf
transgene
basis
Prior art date
Application number
EA201700456A
Other languages
English (en)
Other versions
EA039395B1 (ru
Inventor
Сергей Львович КИСЕЛЕВ
Original Assignee
Общество с ограниченной ответственностью "НекстГен"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "НекстГен" filed Critical Общество с ограниченной ответственностью "НекстГен"
Publication of EA201700456A1 publication Critical patent/EA201700456A1/ru
Publication of EA039395B1 publication Critical patent/EA039395B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Выявлены точечные изменения нуклеотидной последовательности 3'UTR гена vegf, которые существенно увеличивают время жизни продукта его транскрипции - мРНК в клетках млекопитающих. Экспериментальным путем выбрана генная конструкция с оптимальным перечнем выявленных мутаций, характеризующаяся наибольшим временем жизни мРНК. Подтвержден биологический эффект разработанной генной конструкции и фармацевтической композиции на ее основе in vitro и in vivo.
EA201700456A 2015-05-26 2015-12-07 СПОСОБ ПОЛУЧЕНИЯ ГЕННОЙ КОНСТРУКЦИИ И ПЛАЗМИДНАЯ ДНК С УВЕЛИЧЕННЫМ ВРЕМЕНЕМ ЖИЗНИ мРНК ТРАНСГЕНА VEGF В КЛЕТКЕ МЛЕКОПИТАЮЩЕГО, ПЛАЗМИДНАЯ ДНК ГЕНА VEGF165, мРНК, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ПЛАЗМИДНОЙ ДНК EA039395B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2015119768A RU2612497C2 (ru) 2015-05-26 2015-05-26 Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
PCT/RU2015/000852 WO2016190774A1 (ru) 2015-05-26 2015-12-07 Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf

Publications (2)

Publication Number Publication Date
EA201700456A1 true EA201700456A1 (ru) 2018-06-29
EA039395B1 EA039395B1 (ru) 2022-01-21

Family

ID=57392933

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700456A EA039395B1 (ru) 2015-05-26 2015-12-07 СПОСОБ ПОЛУЧЕНИЯ ГЕННОЙ КОНСТРУКЦИИ И ПЛАЗМИДНАЯ ДНК С УВЕЛИЧЕННЫМ ВРЕМЕНЕМ ЖИЗНИ мРНК ТРАНСГЕНА VEGF В КЛЕТКЕ МЛЕКОПИТАЮЩЕГО, ПЛАЗМИДНАЯ ДНК ГЕНА VEGF165, мРНК, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ПЛАЗМИДНОЙ ДНК

Country Status (10)

Country Link
US (2) US9896493B2 (ru)
EP (1) EP3305901B1 (ru)
CN (1) CN107614687B (ru)
AU (1) AU2015396177B2 (ru)
BR (1) BR112017023058B1 (ru)
CA (1) CA2985608C (ru)
EA (1) EA039395B1 (ru)
MX (1) MX2017013206A (ru)
RU (1) RU2612497C2 (ru)
WO (1) WO2016190774A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114908089B (zh) * 2021-02-08 2024-03-15 上海细胞治疗集团有限公司 3’utr的构建方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5587300A (en) * 1994-04-26 1996-12-24 Wisconsin Ulumni Research Foundation Method to increase regulatory molecule production
CA2283461A1 (en) 1997-03-14 1998-09-17 Uab Research Foundation Adenoviral vectors with modified tropism
US6627436B2 (en) 1997-10-31 2003-09-30 Stratagene Vector for gene expression in prokaryotic and eukaryotic systems
CN100471522C (zh) 1998-03-13 2009-03-25 惠氏 聚核苷酸组合物及其制备方法与用途
US7598079B2 (en) * 1998-12-24 2009-10-06 Novation Pharmaceuticals, Inc. Assay for identifying compounds which affect stability of mRNA
WO2000047235A2 (en) 1999-02-10 2000-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of stimulating angiogenesis
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7288521B2 (en) 2000-04-06 2007-10-30 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
CN1351055A (zh) 2000-10-26 2002-05-29 上海博德基因开发有限公司 一种新的多肽——人的血管内皮生长因子165受体(vegf－165r)10.67和编码这种多肽的多核苷酸
WO2003000009A2 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
CN100431611C (zh) 2002-07-04 2008-11-12 朱静亚 多肽－脂质体与人血管内皮生长因子基因重组质粒复合物及用途
AU2003302590B2 (en) 2002-12-02 2008-11-06 Anges Mg, Inc. Compositions for treating or preventing angiogenesis-dependent symptoms
CN101040041A (zh) 2004-09-17 2007-09-19 申特莱恩公司 质粒dna的稳定液体制剂
RU2297848C2 (ru) 2005-05-11 2007-04-27 Александр Веньяминович Иткес Генно-инженерная конструкция vegf-ибмед (vegf-ibmed)
ES2338400B1 (es) 2008-05-06 2011-09-14 David Benet Ferrus Conjunto de moleculas antiangiogenicas y su uso.
AU2010218388B2 (en) 2009-02-24 2015-03-26 The Scripps Research Institute Reengineering mRNA primary structure for enhanced protein production
US8367350B2 (en) 2009-04-29 2013-02-05 Morehouse School Of Medicine Compositions and methods for diagnosis, prognosis and management of malaria
RU2431669C2 (ru) * 2009-06-23 2011-10-20 Государственное образовательное учреждение высшего профессионального образования "Казанский государственный университет им. В.И. Ульянова-Ленина" Способ получения лекарственного препарата генетически модифицированных клеток
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека

Also Published As

Publication number Publication date
RU2015119768A (ru) 2016-12-20
US20160347803A1 (en) 2016-12-01
BR112017023058A2 (pt) 2018-10-16
CN107614687B (zh) 2021-05-28
BR112017023058B1 (pt) 2024-03-05
US10040837B2 (en) 2018-08-07
US20180086800A1 (en) 2018-03-29
CA2985608C (en) 2021-06-15
WO2016190774A1 (ru) 2016-12-01
EP3305901A1 (en) 2018-04-11
CA2985608A1 (en) 2016-12-01
EP3305901A4 (en) 2018-10-24
CN107614687A (zh) 2018-01-19
AU2015396177A1 (en) 2017-11-02
EA039395B1 (ru) 2022-01-21
AU2015396177B2 (en) 2019-02-28
EP3305901B1 (en) 2020-09-30
US9896493B2 (en) 2018-02-20
RU2612497C2 (ru) 2017-03-09
MX2017013206A (es) 2018-02-15

Similar Documents

Publication Publication Date Title
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
EA201991369A1 (ru) Модифицированные направляющие рнк
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
EP3728596A4 (en) CONSTRUCTION OF NUCLEIC ACID ALLOWING THE EXPRESSION OF A GENE IN VITRO AND IN VIVO
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
CY1124327T1 (el) Τροποποιηση της εκφρασης του ιου ηπατιτιδας β (hbv)
EA202191313A1 (ru) Композиции на основе липидных наночастиц
EA201790698A1 (ru) Новые сайты интеграции cho и их применения
ECSP19017082A (es) Regulación de la expresión génica usando nucleasas modificadas
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
CY1120103T1 (el) Κλιμακωσιμο συστημα παραγωγης λεντιικου φορεα, συμβατο με βιομηχανικες φαρμακευτικες εφαρμογες
MX2021008143A (es) Metodos para cosechar cultivos de celulas de mamifero.
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
EA201790789A1 (ru) Композиции и способы, предназначенные для ингибирования экспрессии гена hao1 (оксидазы 1 гидроксикислот (гликолат-оксидазы))
EP4249036A3 (en) Methods and products for nucleic acid production and delivery
MX346923B (es) Genes y proteinas para sintesis de alcanoil-coa.
MX357803B (es) Moléculas de ácido nucleico artificiales.
CY1123119T1 (el) Αντινοηματικο νουκλεϊκο οξυ
BRPI0819526B8 (pt) Sequência de ácido nucleico de precursor de mirna artificial, construção recombinante e método para reduzir a expressão de uma sequência alvo
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
MX358706B (es) Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
UY34227A (es) Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
EA201892588A1 (ru) Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации